38 completed, 11 terminated, 10 withdrawn, 5 unknown. 23 Phase 2, 16 Not applicable, 14 Phase 4, 13 Phase 1, 6 Phase 3.
Follow Lovaza: new trials by email Literature Review of Lovaza trials Research Report on Lovaza
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery Omega-3 Ethyl Esters 4 g, Omega-3 Ethyl Esters 2 g - Postoperative Delirium | Phase 2 | Terminated | University of Missouri-Columbia | 1 | 2026-03-03 | 2026-05-11 |
| Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters - Breast Atypical Hyperplasia, Breast Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2025-07-28 | 2026-08-04 |
| Immunonutrition for Diabetic Foot Ulcers Lovaza, L-Arginine Powder, Vitamin C - Diabetes Mellitus, Diabetic Peripheral Neuropathy | Phase 2 / Phase 3 | Terminated | Prisma Health-Midlands | 1 | 2023-02-08 | 2024-12-27 |
| Altering Lipids for Tolerance of Aromatase Inhibitor Therapy Omega-3 fatty acid supplement - Breast Cancer | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 77 | 2020-07-28 | 2026-05-06 |
| Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE) Omega-3 fatty acid ethyl esters (2 gram) - Colorectal Cancer, Lynch Syndrome | Phase 2 | Unknown | University of Kansas Medical Center | 21 | 2019-02-06 | 2023-06-01 |
| QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC avelumab, bevacizumab, capecitabine - Colorectal Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-08-01 | 2025-02-21 | |
| Pro-Resolving Mediators in Acute Inflammation in Humans Lovaza, Cantharone, Phlebotomy - Inflammation; Skin, Resolution | Early Phase 1 | Completed | Brigham and Women's Hospital | 19 | 2018-07-02 | 2022-05-26 |
| QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors avelumab, Bevacizumab, Capecitabine - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-02-01 | 2025-02-21 | |
| QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy Aldoxorubicin HCl, ALT-803, ETBX-011 - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 4 | 2017-12-28 | 2024-05-22 |
| QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy avelumab, bevacizumab, capecitabine - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy Avelumab, Bevacizumab, Capecitabine - Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-24 | |
| QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL avelumab, bevacizumab, capecitabine - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-24 | |
| QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy avelumab, bevacizumab, capecitabine - Urothelial Carcinoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy ALT-803, ETBX-011, GI-4000 - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | ImmunityBio, Inc. | 6 | 2017-11-06 | 2024-12-12 |
| Derivatives of Omega-3 HUFA as Biomarkers of Traumatic Brain Injury Omega 3 fatty acid, Safflower seed oil - TBI | Phase 2 | Withdrawn | University of Pennsylvania | 2017-01-01 | 2022-10-13 | |
| Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel Omega-3 fatty acid, Placebo, Paclitaxel - Breast Cancer, Ovarian Neoplasm | Not applicable | Completed | New Mexico Cancer Research Alliance | 60 | 2016-05-24 | 2022-10-05 |
| Study to Evaluate the Acute Bioavailability of EPA and DHA From a DietarySupplement in Healthy Men and Women Wax Ester Marine Oil, Ethyl Ester Marine Oil - Healthy | Not applicable | Completed | Calanus | 18 | 2015-03-01 | 2016-08-12 |
| An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis Epanova, Lovaza - Severe Hypertriglyceridemia | Phase 1 | Completed | AstraZeneca | 30 | 2014-10-01 | 2016-06-20 |
| Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women LOVAZA, GnRH - Obesity, Fertility | Not applicable | Completed | University of Colorado, Denver | 39 | 2014-07-01 | 2017-02-02 |
| Fish Oils and Adipose Inflammation Reduction Lovaza, Placebo - Obesity | Phase 4 | Completed | University of Pennsylvania | 29 | 2014-06-01 | 2019-02-12 |
Showing 20 of 65. Sign in to see all of them.
Hypertriglyceridemia (14) · Breast Neoplasms (5) · Cardiovascular Diseases (5) · Diabetes Mellitus (4) · HIV Infections (4) · Non-alcoholic Fatty Liver Disease (4) · Colorectal Neoplasms (3) · Dyslipidemias (3) · Fatty Liver (3) · Inflammation (3) · Obesity (3) · Coronary Artery Disease (2) · Heart Diseases (2) · Hypercholesterolemia (2) · Insulin Resistance (2)
ImmunityBio, Inc. (8) · Provident Clinical Research (4) · University of Pennsylvania (3) · Washington University School of Medicine (3) · AstraZeneca (2) · Massachusetts General Hospital (2) · Penn State University (2) · Sanford Research (2) · Takeda (2) · Tufts University (2) · Babu Balagopal (1) · Boston Children's Hospital (1) · Boston University (1) · Brigham and Women's Hospital (1) · Calanus (1)
United States (53) · Canada (1) · United Kingdom (1)
Kevin C. Maki, PhD (3) · Associate Professor, Clinical Cell Biology and Medicine (2) · Bettina Mittendorfer, PhD (2) · Christine A Wanke, MD (2) · Aaron I Vinik, MD, PhD (1) · Alex Pokov, MD (1) · Alex Polotsky, MD, MS (1) · Andrea L Lawless, MD (1) · Andrea Manni, MD (1) · Ann C Skulas-Ray, B.S. (1) · Anwaar Saeed, MD (1) · Bruce D Levy, MD (1) · Carine M Lenders, MD, MS, ScD (1) · Carlin S Long, MD (1) · Chad Cook, PhD (1)
PMID 21297494, PMID 15290734, PMID 18678300, PMID 19644030, PMID 21159787, PMID 21159789, PMID 21501117, PMID 21621252, PMID 21775113, PMID 21818149, PMID 21870979, PMID 22865498, PMID 23130172, PMID 23293330, PMID 23328126, PMID 23592752, PMID 24743428, PMID 24988179, PMID 25043514, PMID 25393536, PMID 25852206, PMID 25994567, PMID 26021488, PMID 26272871, PMID 26523525, PMID 26602219, PMID 26631058, PMID 26748347, PMID 27012629, PMID 27106721, PMID 28294174, PMID 28424185, PMID 30773100, PMID 32473640, PMID 32620337, PMID 34291724, PMID 37847317, PMID 9048514
5UL1TR000135 (1), K23DK095913 (1), KL2TR000136 (1), P01GM095467 (1), P20RR021954 (1), P30CA046592 (1), P50HL083799 (1), R01CA160938 (1), R01HL096585 (1), T32DK007352 (1), U24DK100469 (1), U54HD058155 (1), UG1CA242632 (1)